Pharmaceuticals
I-Mab Files Shelf Registration Statement for PIPE Investors
SHANGHAI and GAITHERSBURG, Md., Dec. 1, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today filed a registration statement on Form F-1 with the Securities and ...
2020-12-02 05:23
10037
Bora Pharmaceuticals completes acquisition of former GSK facility
MISSISSAUGA, ON, Dec. 1, 2020 /PRNewswire/ -- Bora Pharmaceuticals Co., Ltd announced today that the contract development and manufacturing organization (CDMO) has successfully completed the acquisition of GSK'sMississauga, Ontario (Canada) facility. Initially announced in March 2020, the s...
2020-12-01 23:57
7217
I-Mab Appoints Leading Immunology and Hematology Experts to Its Scientific Advisory Board
SHANGHAI and GAITHERSBURG, Md., Dec. 1, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the strengthening of its Scientific Advisory Board ("SAB"...
2020-12-01 21:00
3224
Varian Partners with Sony Foundation Australia in the You Can Stay Program
PALO ALTO, Calif., Nov. 30, 2020 /PRNewswire/ -- Varian (NYSE: VAR) today announced it has entered a partnership with Sony Foundation Australia to support its You Can Stay Program. The You Can Stay program provides free accommodations for cancer patients aged between 15 to 25 and their families i...
2020-11-30 05:15
3791
Breakthrough in AML Treatment: GoldenBiotech Reports New Drug Trial of Antroquinonol -Outperforms Listing Drugs in Relapsed Acute Myeloid Leukemia
TAIPEI, Nov. 26, 2020 /PRNewswire/ -- Golden Biotechnology Corp.(GoldenBiotech, 4132.TWO), a leading Taiwanese biopharmaceutical company, announces that its new drug Antroquinonol (HOCENA®) outperforms the other listing drugs for the treatment of relapsed AML (acute myeloid leukemia) patients in ...
2020-11-26 21:35
2433
Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations
TAIPEI and SAN DIEGO, Nov. 25, 2020 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that it has submitted multiple Investigational New D...
2020-11-26 10:34
1943
China Biologic Reports Financial Results for the Third Quarter of 2020
BEIJING, Nov. 24, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced its unaudited financial results for the third quarter of 2020. Third Quarter...
2020-11-25 05:30
12097
OliPass Announces Formation of Scientific Advisory Board of Pioneers in Sodium Ion Channellopathy and Pain
SEOUL, South Korea, Nov. 24, 2020 /PRNewswire/ -- OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced to commission a Scientific Advisory Board ("SAB") of key experts in sodium ion channelopathy and pain. The SAB will advise OliPass on th...
2020-11-24 22:00
1955
Novel Antioxidant Seen as an Effective Strategy for Peripheral Artery Disease
OMAHA, Ne., Nov.20, 2020 /PRNewswire/ -- Researchers within the School of Health and Kinesiology at theUniversity of Nebraska at Omaha (UNO) have found that a novel antioxidant can provide a number of health benefits for individuals with peripheral artery disease. The antioxidant specifically ta...
2020-11-20 23:07
2343
CARsgen Therapeutics to Present Multiple Myeloma Cell Therapy Data at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition in December
SHANGHAI, Nov. 20, 2020 /PRNewswire/ -- CARsgen Therapeutics, a clinical-stage biopharmaceutical company, today announced that data from its global multiple myeloma program will be presented, including two oral presentations and one poster session, at the 62nd American Society of Hematology (ASH)...
2020-11-20 19:00
3426
China Biologic Enters into Definitive Merger Agreement for Going Private Transaction
BEIJING, Nov. 19, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that it has entered into a definitive Agreement and Plan of Merger (the "Merg...
2020-11-19 21:09
9146
VolitionRx Limited to Present COVID-19 Data at MEDICA 2020
AUSTIN, Nov. 19, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases, has announced that Dr.Mark Eccleston, a founding sci...
2020-11-19 20:00
7404
Samsung Biologics breaks ground on Super Plant, the world's largest and most innovative bio-manufacturing facility
INCHEON, South Korea, Nov. 18, 2020 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) officially began construction of its Plant 4 in Incheon,South Korea. Dubbed the "Super Plant," the new, multi-story 238,000-square-meter construction will be the world's largest biopharmaceutical manufacturing ...
2020-11-18 20:00
1776
Samsung Biologics announces strategic manufacturing partnership with Lilly to accelerate delivery of COVID-19 antibody treatments
INDIANAPOLIS and INCHEON, South Korea, Nov. 17, 2020 /PRNewswire/ -- Samsung Biologics' partnership with Eli Lilly and Company is expected to greatly accelerate the global supply for Lilly's COVID-19 antibody therapies through a long-term manufacturing agreement, with the ultimate goal of making ...
2020-11-17 20:00
1573
Foresee Pharmaceuticals Enters Exclusive License Agreement with GenSci for the Commercialization of Camcevi(TM) in China
TAIPEI, Nov. 17, 2020 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO) ("Foresee") announced today that it has entered into an exclusive license agreement with GenScience Pharmaceuticals ("GenSci") - a wholly-owned subsidiary of Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ) - for ...
2020-11-17 17:51
1978
CPhI & P-MEC China 2020 adapts to customer needs with hybrid pharma event
SHANGHAI, Nov. 17, 2020 /PRNewswire/ -- CPhI & P-MEC China
2020-11-17 15:00
1600
Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases
MELBOURNE, Australia, Nov. 16, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the allowance of a new composition of matter patent by the United States Patent and Trademark Office (USPTO). The new patent is the product of in-ho...
2020-11-16 21:42
2799
Happiness Biotech Starts Offering Kingdomway Coenzyme Q10 in Its Experience Stores
NANPING, China, Nov. 16, 2020 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovativeChina-based nutraceutical and dietary supplements producer, announced today that the Company's experience stores started offering Coenzyme Q10 - a best-selling product from ...
2020-11-16 21:00
3104
PharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020
DAEJEON, South Korea, Nov. 16, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks) announced today that the company will present the final results of the Phase IIa clinical trial of Olinvacimab for rGBM (recurrent glioblastoma multiforme) patients at SNO (Society of Neuro-Oncology) 2020. ...
2020-11-16 21:00
1409
PTC Therapeutics Announces Initiation of Phase 2/3 Clinical Trial in Australia to Evaluate PTC299 for the Treatment of COVID-19
– Oral treatment with novel dual-mechanism of action has the potential to address the two critical elements of COVID-19: viral replication and uncontrolled inflammatory response – – Randomized, double-blind, placebo-controlled, Phase 2/3 clinical study with two stages initiated at several sites ...
2020-11-16 05:00
1570
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
8546
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7700